Title: Cost-Effectiveness of 2+1 Dosing of 13-Valent and 10-Valent Pneumococcal Conjugate Vaccines in Canada
|
|
- Walter Phillips
- 6 years ago
- Views:
Transcription
1 Author's response to reviews Title: Cost-Effectiveness of 2+1 Dosing of 13-Valent and 10-Valent Pneumococcal Conjugate Vaccines in Canada Authors: Stephanie R Earnshaw (searnshaw@rti.org) Cheryl L McDade (cmcdade@rti.org) Giovanni Zanotti (giovanni.zanotti@pfizer.com) Raymond A Farkouh (rfarkouh@pfizer.com) David Strutton (david.strutton@pfizer.com) Version: 2 Date: 30 March 2012 Author's response to reviews: see over
2 Peer Review Report BMC Infectious Disease Cost-effectiveness of 2+1 Dosing of 13-Valent and 10-Valent Pneumococcal Conjugate Vaccines in Canada Dear Dr. Principi: MS: Thank you for the reviewer / editorial comments in response to our manuscript entitled Costeffectiveness of 2+1 Dosing of 13-Valent and 10-Valent Pneumococcal Conjugate Vaccines in Canada. We thank the reviewers for their constructive feedback which has helped add clarity and has significantly improved the quality/presentation of the manuscript. We believe that we have satisfactorily addressed the comments within the manuscript text. Please find below our responses to each comment (in italics). We have submitted a revised manuscript after incorporating the changes. In this submission, we have submitted eight Microsoft Word documents: Earnshaw Vaccine Manuscript 30March2012 with Highlights(Sent).docx: manuscript with highlighted changes Earnshaw Vaccine Manuscript 30March2012(Sent).docx a clean version of the manuscript Earnshaw Vaccine Appendix 30March2012(Sent).docx a clean version of the appendix. Earnshaw Figure 1 Model Structure 30March2012(Sent).jpg a clean version of Figure 1 Earnshaw Figure 2 Breakeven Analysis 30March2012(Sent).jpg a clean version of Figure 2 Earnshaw Figure 3a Change in PCV7 Serotype Coverage Over Time 30March2012(Sent).jpg a clean version of Figure 3a Earnshaw Figure 3b Serotypes-Coverage for All Pneumococcal Vaccines Over Time 30March2012(Sent).jpg a clean version of Figure 3b Earnshaw Figure 4 Sensitivity Analysis Results 30March2012(Sent).jpg a new, clean version of Figure 4 Please feel free to contact me if you have further questions. We look forward to hearing from you. Sincerely,
3 Stephanie Earnshaw Reviewer's Comments Reviewer 1: Kristina Bryant Reviewer's report: Major Compulsory Revisions Earnshaw and colleagues compare the cost-effectiveness of a 2+1 dosing schedule of PCV13 to PCV10. This sort of analysis is important and can help inform vaccine policy decisions. Response: thanks However, when all of the authors are employed by or paid the pharmaceutical company that owns the product favored by the analysis, is important to avoid even the hint of bias. On page 11, the authors state that PCV10 is less immunogenic than PCV across the 7 common serotypes. In fact, using WHO defined criteria, PCV10 was non-inferior to PCV7 for serotypes 4, 9V, 14, 18C and 19F. Lower antibody responses were seen for serotypes 6B and 23F. This misrepresentation detracts from the manuscript and the important conclusions it draws. Response: We have clarified this statement in the Direct Effects section. There is also a tendency to emphasize potential disadvantages of PCV10, such as inconsistent effects on pneumococcal carriage, while conversely emphasizing potential advantages of PCV13. The authors make generous assumptions in estimating the indirect effects of PCV13 that may be valid but are not sufficiently supported by the data provided. The authors do acknowledge in the limitations that indirect effects of PCV13 have not been proved. Response: We acknowledge the reviewer s point here. A recent study by the Centers for Disease Control was recently presented at the 8 th International Symposium on Pneumococci & Pneumococcal Diseases. In this study, the CDC reports that PCV13- type IPD is declining among adults (i.e.,nonvaccinated individuals) in the US. (Moore M, Link-Gelles R, Farley M, Schaffner W, Thomas A, Reingold A, Harrison L, Lexau C, Zansky S, Petit S, Gershman K, Scherzinger K, Juni B, Beall B, Whitney C. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, United States, Presented at 8 th International Symposium on Pneumococci & Pneumococcal Diseases. 13March2012.) As a result of this new evidence, we have updated the text in the 1 st paragraph of the Direct Effect section and the 7 th paragraph in the Discussion section. The authors acknowledge that their results are somewhat different than those reported by investigators who based their analysis on pneumococcal epidemiology from Alberta.
4 One is left to wonder if Quebec data was used because it supported the hypothesis that PCV13 is always dominant vs PCV10. Given regional differences in the epidemiology of pneumococcal vaccine, it should be noted that this analysis is may or may overestimate or underestimate cost-effectiveness for the nation as a whole. Response: We see the reviewers point here. We used the Quebec data because it represents the most recently available epidemiology data. Since the introduction of PCV7, there has been a dramatic drop in disease and PCV7-typed disease. As a result, our guess is that ensuring that we are using the most recent epidemiology data is perhaps more important than ensuring that region specific data are used. Comparing the incidence of IPD that we could use between the different sources, we find that the incidence derived from the Quebec data is actually lower than the IPD incidence reported as being used by Chuck et al (2010) and Morrow et al (2009). Also, looking at Figure 3a, we see that the incidence of PCV7 serotypes are similar between all Canada (i.e., Bettinger et al data), Quebec, and Alberda (Kellner et al data) where the more recent data are available for Quebec than the other regions. We updated the text in the 1 st paragraph in the Incidence section and the 3 rd paragraph of the Discussion section to note this. Reviewer 2: Maurizio de Martino Reviewer's report: This is a very good paper, well written, with an excellent study design. Results are clearly reported and well discussed. I think that the paper can be accepted, provided some minor changes: 1. avoid the term "patients" (as in methods in the abstract or at page 8...). Children are healthy when they are vaccinated; Response: great point! We have revised the text throughout the manuscript to replace the word patient. 2. erase at page 7, line 5, the comma between PNE and hospitalized; Response: great catch! We have deleted the comma. 3. the authors must decide: or Streptococcus pneumoniae or S. pneumoniae, always throughout the text; Response: great point! We have revised the text throughout the manuscript. 4. the authors must discuss more deeply the bias of the acquisition cost of PCV10 which was not available. Response: We have updated text in the last paragraph in the Discussion section. We also performed additional sensitivity analyses around the impact of changes in results when changing the cost per dose of PCV10 while holding the cost per dose of PCV13 constant. We have updated the text in the last paragraph in the Base-case Results section. Reviewer 3: Paolo Bonanni Reviewer's report:
5 The manuscript deals with a very interesting and up-to-date subject. The methods are well described, and the discussion and conclusions sound reasonable. Most limitations are recognized, and the overall writing of the article is very good. Response: thank you very much. Discretionary Revisions A clear limitation regards the fact that the data on serotype coverage for IPD for PCV10 and PCV13 were obtained by a personal communication. Since the Authors report that such communication was made on March 21, 2011, it is difficult to understand why such data are still unpublished, at least in some official document if not in a scientific journal. Correctly, the Authors also used other sources of data for serotype coverage, but since the baseline results make reference to such personal communication, the possibility to cite a published source would be beneficial for the article. Were those data finally published? Response: The reviewer has a great point. There is a manuscript that has been developed, but it is currently under review with a journal. In the meantime, we have updated the citation with a reference to a public presentation of these data. Minor Essential Revisions Another point to clarify regards what is illustrated also in Figure 2, i.e. the data (reported at page 18) on the possibility that Assuming a total per-dose cost of PCV10 of $94.10 (acquisition and administration) and considering a threshold incremental cost per QALY of $50,000, the cost per dose for PCV13 could be as high as $ for PCV13 to remain cost-effective, when both direct and indirect effects were considered. Since these data seem to me to be contradictory with what reported in the Discussion section (page 23) where it is stated that When including indirect effects, our model was not sensitive to PCV13 price variation; PCV13 remained a cost-saving option even if PCV13 was twice the price of PCV10, I would ask the Authors to explain better this apparent contradiction. Response: These statements are actually not contradictory. The first statement says that when a cost of $94.10 per dose for PCV10 is assumed, the cost of PCV13 could be as high as $ per dose and PCV13 would be cost-effective (i.e., incremental cost per QALY=$50,000). At a cost per dose that is approximately twice the cost of PCV10 ($ or 110% increase in PCV10 cost per dose), PCV13 and PCV10 are cost neutral. As a result, the cost per dose for PCV13 can change a lot from the assumed parity with PCV10 and still be cost-effective. We have updated the text in the Result section to clarify the cost per dose and the percent increase in cost per dose of PCV13 when cost neutrality occurs. Other two points, always regarding the pricing issue, would make the manuscript look more balanced. The first is a further sensitivity analysis where the price of PCV10 might be made lower than that fixed as invariable ($94.10), vis-à-vis the lower coverage afforded by the 10-valent versus the 13-valent vaccine (and the consequent possibility that the producer of PCV10 might decide to offer it at a lower price). Response: Great point. We performed this analysis and added the results to the 4 th paragraph in the Results-Base Case Analysis section.
6 The other point regards the possibility that, given the fact that indirect effects of the new conjugate vaccines are not demonstrated in a definitive way, it would be better, in my opinion, to draw a baseline scenario where neither PCV13 nor PCV10 have an indirect effect, leaving all the other possibilities presented in the manuscript as sensitivity analyses. Response: We acknowledge the reviewer s point here. A recent study by the Centers for Disease Control was recently presented at the 8 th International Symposium on Pneumococci & Pneumococcal Diseases. In this study, the CDC reports that PCV13- type IPD is declining among adults (i.e.,nonvaccinated individuals) in the US. (Moore M, Link-Gelles R, Farley M, Schaffner W, Thomas A, Reingold A, Harrison L, Lexau C, Zansky S, Petit S, Gershman K, Scherzinger K, Juni B, Beall B, Whitney C. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, United States, Presented at 8 th International Symposium on Pneumococci & Pneumococcal Diseases. 13March2012). As a result of this new evidence, we feel that assuming indirect effects for PCV13 is appropriate. We have updated the text in the 1 st paragraph of the Direct Effect section and the 7 th paragraph in the Discussion section to present this new evidence. Do note we do also present a base case analysis in which we assume direct effects only. Let us know if we should address this differently. Table 6 seems very long and crowded. If possible, an alternative way of presenting these crucial data for the article should be explored. Response: Great point! We have updated Table 6 to be presented as a figure. This is now inserted as Figure 4.
Title: Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants
Author's response to reviews Title: Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants Authors: Simon Rueckinger (simon.rueckinger@med.uni-muenchen.de)
More informationImpact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA
Impact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA San Jose, Costa Rica, August 2007 Pneumococcal Conjugate Vaccine Introduction
More informationCUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 2005 TO DATE
CUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 5 TO DATE GERMS-SA surveillance programme http://www.nicd.ac.za/?page=germs-sa&id=97 National, active,
More informationCost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar
CPHA 2009 Cost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar Ismaila AS 1,2, Pereira JA 1, Robson RC 1, Rawson NS 1, Simpson SD 1, Standaert BA 3
More informationSetting The setting was primary care. The economic study was carried out in Norway.
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program Wisloff T, Abrahamsen T G, Bergsaker M A, Lovoll O, Moller P, Pedersen M K, Kristiansen
More informationImpacto de la vacuna conjugada en EUA
Impacto de la vacuna conjugada en EUA Richard Facklam, PhD, Distinguished Consultant, Retired, Centers for Disease Control and Prevention Atlanta, GA Bogotá, Colombia, February 2008 Pneumococcal Conjugate
More informationCumulative invasive pneumococcal disease case numbers reported by the GERMS-SA surveillance programme, 1 January 2012 to 30 April 2018
Cumulative invasive pneumococcal disease case numbers reported by the GERMS-SA surveillance programme, 1 January 212 to 3 April 218 GERMS-SA surveillance programme GERMS-SA is a national, active, laboratory-based
More informationCumulative invasive pneumococcal disease case numbers reported by the GERMS-SA surveillance programme, 1 January 2012 to 31 October 2018
Cumulative invasive pneumococcal disease case numbers reported by the GERMS-SA surveillance programme, 1 January 212 to 31 October 218 GERMS-SA surveillance programme GERMS-SA is a national, active, laboratory-based
More informationEconomic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland
Volume 11 Number 5 2008 VALUE IN HEALTH Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Lesley Tilson, BSc (Pharm), PhD, 1 Cara Usher, BSc, PhD, 1 Karina
More informationSetting The setting was community. The economic study was carried out in the USA.
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children Lieu T A, Ray G T, Black S R, Butler J C, Klein J O, Breiman R F, Miller M A, Shinefield H R Record
More informationUse of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Polysaccharide Vaccine in Adults with Immunocompromising Conditions
Use of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Polysaccharide Vaccine in Adults with Immunocompromising Conditions Tamara Pilishvili, MPH Respiratory Diseases Branch National Center for
More informationPotential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada
CPHA 2010 Potential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada Afisi S. Ismaila a,b, Jennifer A. Pereira c, Reid C. Robson a, Gerhart Knerer d a Medical
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationAuthor's response to reviews
Author's response to reviews Title: Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination Authors: Grant
More informationTitle: Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization
Author s response to reviews Title: Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization Authors: Margarita Riera-Montes (margarita.riera@p-95.com)
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationPneumococcal vaccination for older persons. No. 2018/05. Executive summary
Pneumococcal vaccination for older persons No. 2018/05 Executive summary Executive summary Pneumococcal vaccination for older persons page 2 of 6 Many people carry pneumococcal bacteria without becoming
More informationPneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA
Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure
More informationAuthor's response to reviews
Author's response to reviews Title: Diabetes duration and health-related quality of life in individuals with onset of diabetes in the age group 15-34 years - a Swedish population-based study using EQ-5D
More informationAuthor's response to reviews
Author's response to reviews Title: An open-label randomized clinical trial of prophylactic paracetamol co-administered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus
More informationIID&GHTP. Pneumococcal vaccine Africa décembre By: Julie Lajoie
IID&GHTP Pneumococcal vaccine Africa décembre 2011 By: Julie Lajoie General information Ecology and Epidemiology of invasive pneumococcal disease (IPD) in sub Saharan Africa is different from that seen
More informationPrevention of pneumococcal disease in Canadian adults Old and New. Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto
Prevention of pneumococcal disease in Canadian adults Old and New Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Objectives Review epidemiology of pneumococcal disease in adults
More informationAuthor's response to reviews
Author's response to reviews Title: An open-label randomized clinical trial of prophylactic paracetamol co-administered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus
More informationCost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
Adv Ther (2014) 31:392 409 DOI 10.1007/s12325-014-0115-y ORIGINAL RESEARCH Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States Jieling Chen Megan A. O Brien H. Keri Yang John D.
More informationTitle: Enhancing state-based surveillance for invasive pneumococcal disease
09-ID-06 Committee: Infectious Diseases Title: Enhancing state-based surveillance for invasive pneumococcal disease I. tatement of the Problem: Cases of invasive pneumococcal disease among children less
More informationCurrent Status of PCV Use and WHO Recommendations
Current Status of PCV Use and WHO Recommendations SAGE 18 October 2017 Kate O Brien, MD MPH 1 Pneumonia remains a major cause of child deaths LMIC LMIC Pneumonia HIC HIC Pneumonia ~16% ~5% 2015 Black,
More informationAnnual Epidemiological Report
August 2018 Annual Epidemiological Report Key Facts Streptococcus 1Pneumoniae (invasive) in Ireland, 2017 In 2017, 415 confirmed cases of invasive pneumococcal diseases (IPD) were reported in Ireland,
More informationTitle: Co-morbidities, complications and causes of death among people with femoral neck fracture - A three-year follow-up study.
Author s response to reviews Title: Co-morbidities, complications and causes of death among people with femoral neck fracture - A three-year follow-up study. Authors: Monica Berggren (monica.langstrom@umu.se)
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar July 2017 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationTitle:The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers.
Author's response to reviews Title:The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and Authors: Helen Cavanagh (helen21987@hotmail.com) Katherine MA Rogers (k.rogers@qub.ac.uk) Version:3Date:1
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar February 2016 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Ball State University
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationTitle:The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers.
Author's response to reviews Title:The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Authors: Helen Cavanagh (helen21987@hotmail.com) Katherine MA Rogers (k.rogers@qub.ac.uk)
More informationWould a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children?
Would a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children? Philippe De Wals Department of Social and Preventive Medicine, Laval University Quebec University Hospital
More informationManuscript ID BMJ R1 entitled "Education and coronary heart disease: a Mendelian randomization study"
BMJ - Decision on Manuscript ID BMJ.2017.03 7504.R1 Body: 11-May-2017 Dear Dr. Tillmann Manuscript ID BMJ.2017.037504.R1 entitled "Education and coronary heart disease: a Mendelian randomization study"
More informationMeasure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health
Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:
More informationTitle: Identifying work ability promoting factors for home care aides and assistant nurses
Author's response to reviews Title: Identifying work ability promoting factors for home care aides and assistant nurses Authors: Agneta Larsson (agneta.larsson@ltu.se) Lena Karlqvist (lena.karlqvist@ltu.se)
More informationGaston De Serres, MD, PhD, INSPQ Vaccine Sciences Symposium Wednesday, April 7, 2010 Hart House, University of Toronto
Is more always better: incorporating the concepts of incremental and marginal trade-offs in vaccine program design Gaston De Serres, MD, PhD, INSPQ Vaccine Sciences Symposium Wednesday, April 7, 2010 Hart
More informationTitle: Sports activity and combined use of snus and cigarette smoking among young males in Finland in
Author's response to reviews Title: Sports activity and combined use of snus and cigarette smoking among young males in Finland in 1999-2010 Authors: Ville M Mattila (ville.mattila@uta.fi) Susanna Raisamo
More informationPneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
More informationAuthor's response to reviews
Author's response to reviews Title: Measles transmission from an anthroposophic community to the general population, Germany 2008 - Effect of early intervention on size and duration of measles clusters
More informationTitle: Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives
Author s response to reviews Title: Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives Authors: Robert Beckett (rdbeckett@manchester.edu) Kathryn
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationInvasive pneumococcal disease in non-indigenous people in north Queensland,
Invasive pneumococcal disease in non-indigenous people in north Queensland, 2001 2009 Jeffrey N Hanna, Jan L Humphreys, Denise M Murphy and Helen V Smith Although pneumococcal vaccines had been available
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More informationTo view past issues, go to: The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
From the Texas Department of State Health Services Immunization Branch The goal of the Vaccine Advisory is to disseminate, in a timely manner, practical information related to vaccines, vaccine-preventable
More informationAuthor s response to reviews
Author s response to reviews Title: Lifestyle-related factors that explain disaster-induced changes in socioeconomic status and poor subjective health: a cross-sectional study from the Fukushima Health
More informationPlease revise your paper to respond to all of the comments by the reviewers. Their reports are available at the end of this letter, below.
Dear editor and dear reviewers Thank you very much for the additional comments and suggestions. We have modified the manuscript according to the comments below. We have also updated the literature search
More informationAuthor's response to reviews
Author's response to reviews Title: A multicentre, double-blind, randomised, controlled, parallel-group study of the effectiveness of a pharmacist-acquired medication history in an emergency department
More information# BMJ entitled " Complete the antibiotic course to avoid resistance ; non-evidence-based dogma which has run its course?
Dear Dr. Llewelyn # BMJ.2017.037542 entitled " Complete the antibiotic course to avoid resistance ; non-evidence-based dogma which has run its course?" Thank you for sending us this paper and giving us
More informationConflict of interest in randomised controlled surgical trials: Systematic review, qualitative and quantitative analysis
Reviewer Assessment Open Access P. Probst, K. Grummich, U. Klaiber, P. Knebel, A.Ulrich, M. W. Büchler, and M. K. Diener* Conflict of interest in randomised controlled surgical trials: Systematic review,
More informationGeographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States
MAJOR ARTICLE Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States Jennifer B. Rosen, 1,2 Ann R. Thomas, 3 Catherine A. Lexau,
More informationTitle:Efficacy of Moringa oleifera leaf powder as a hand- washing product: a cross-over controlled study among healthy volunteers.
Author's response to reviews Title:Efficacy of Moringa oleifera leaf powder as a hand- washing product: a cross-over controlled study among healthy volunteers. Authors: Belen Torondel (belen.torondel@lshtm.ac.uk)
More informationIntroduction and overview of the program; new vaccine pipeline and prioritization process
Immunization for the Modern Family: Western Canada Immunization Forum 2011 Introduction and overview of the program; new vaccine pipeline and prioritization process Monika Naus, MD, MHSc, FRCPC, FACPM
More informationIntroduction to Assignments #8 & #9: Writing a Scientific Paper on Nutraceuticals
Dr. Glaser, Scientific Writing, Chem3700, Spring 2014 Introduction to Assignments #8 & #9: Writing a Scientific Paper on Nutraceuticals Science at its very core is data-based, rational analysis and the
More informationPneumococcal Vaccines The Impact Of Conjugate Vaccine
Pneumococcal Vaccines The Impact Of Conjugate Vaccine 1 / 5 2 / 5 3 / 5 Pneumococcal Vaccines The Impact Of Pneumococcal vaccine. The pneumococcal vaccine protects against serious and potentially fatal
More information14/10/16. Background. Streptococcus pneumoniae (Sp) is an important cause for these diseases
Estimates of the potential public health impact and cost-effectiveness of adopting pneumococcal vaccination in the routine immunization programme in African GAVI countries: a modelling study C. Sauboin
More informationReview of Serotype Replacement in the Setting of PCV7 Use and Implications for the PCV10/PCV13 Era
Review of Serotype Replacement in the Setting of PCV7 Use and Implications for the PCV10/PCV13 Era Background Seven-valent pneumococcal conjugate vaccine (PCV7) was first introduced in the United States
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationHealth technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were:
Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease De Wals P, Nguyen V H, Erickson L J, Guay M, Drapeau J, St-Laurent J Record Status This is a critical
More informationMolecular characterization of Streptococcus pneumoniae invasive serotype 19A isolates from adults in two Spanish regions ( )
DOI 10.1007/s10096-011-1399-3 ARTICLE Molecular characterization of Streptococcus pneumoniae invasive serotype 19A isolates from adults in two Spanish regions (1994 2009) J. M. Marimón & M. Alonso & D.
More informationTitle:Continuity of GP care is associated with lower use of complementary and alternative medical providers A population-based cross-sectional survey
Author's response to reviews Title:Continuity of GP care is associated with lower use of complementary and alternative medical providers A population-based cross-sectional survey Authors: Anne Helen Hansen
More informationSystematic review of pneumococcal conjugate vaccine schedules: Executive summary of findings about reduced dose schedules
Systematic review of pneumococcal conjugate vaccine schedules: Executive summary of findings about reduced dose schedules Pippa Scott, 1 Matthias Egger, 1 Anne W.S. Rutjes, 1,2 Lilian Bermetz, 1 Nadège
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Pneumococcal disease, invasive Revised December 2014 Pneumococcal disease, invasive 1.0 Provincial
More informationBCG vaccine and tuberculosis
PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious
More information11 September Tower Old Broad Street London EC2N 1HQ United Kingdom t + 44 (0) f + 44 (0)
11 September 2007 Jim Sylph International Auditing and Assurance Standards Board 545 5th Avenue, 14th Floor New York, New York 10017 USA Edcomments@ifac.org Tower 42 25 Old Broad Street London EC2N 1HQ
More informationTitle: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry
Author's response to reviews Title: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry Authors: Johan Maertens (johan.maertens@uz.kuleuven.ac.be)
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE
Last Updated: Version 4.4 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Immunization Set Measure ID#: Measure Information Form Collected For: CMS Voluntary Only The Joint Commission
More informationTitle: Attitude toward Contraception and Abortion among Curacao women. Ineffective contraception due to limited sexual education?
Author's response to reviews Title: Attitude toward Contraception and Abortion among Curacao women. Ineffective contraception due to limited sexual education? Authors: Marian J. van den Brink (marianvdbrink@hotmail.com)
More informationMathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales Yoon Hong Choi 1 *, Mark Jit 1,2, Stefan Flasche 1,3, Nigel Gay 4, Elizabeth
More informationTitle: A Prospective Study of Dietary Selenium Intake and Risk of Type 2 Diabetes
Author's response to reviews Title: A Prospective Study of Dietary Selenium Intake and Risk of Type 2 Diabetes Authors: Saverio Stranges (S.Stranges@warwick.ac.uk) Sabina Sieri (Sabina.Sieri@istitutotumori.mi.it)
More informationImmunization Update: Pneumonia Vaccines
Immunization Update: Pneumonia Vaccines Barbara Resnick, PhD, CRNP, FAAN University of Maryland *Barbara Resnick has no disclosures/no conflicts of interest What Do We Know? An estimated 40,000 to 50,000
More informationMeasure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health
Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process
More informationRisk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane:
Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane: A retrospective review Xandré Dearden www.up.ac.za IPD: disease spectrum and epidemiology
More informationTitle: The effects of videogames therapy on balance and attention in chronic ambulatory traumatic brain injury: an exploratory study.
Author s response to reviews Title: The effects of videogames therapy on balance and attention in chronic ambulatory traumatic brain injury: an exploratory study. Authors: sofia straudi (s.straudi@ospfe.it)
More informationTitle:Prediction of poor outcomes six months following total knee arthroplasty in patients awaiting surgery
Author's response to reviews Title:Prediction of poor outcomes six months following total knee arthroplasty in patients awaiting surgery Authors: Eugen Lungu (eugen.lungu@umontreal.ca) François Desmeules
More informationTitle: Home Exposure to Arabian Incense (Bakhour) and Asthma Symptoms in Children: A Community Survey in Two Regions in Oman
Author's response to reviews Title: Home Exposure to Arabian Incense (Bakhour) and Asthma Symptoms in Children: A Community Survey in Two Regions in Oman Authors: Omar A Al-Rawas (orawas@squ.edu.om) Abdullah
More informationschedule modifications in the UK
Epidemiology and Infection cambridge.org/hyg Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK Original Paper Cite this article: Wasserman
More informationTips on Successful Writing and Getting Published Rita F. Redberg, MD, MSc, FACC, FAHA Professor of Medicine Editor, JAMA Internal Medicine
Tips on Successful Writing and Getting Published Rita F. Redberg, MD, MSc, FACC, FAHA Professor of Medicine Editor, JAMA Internal Medicine Rita F. Redberg, MD, MSc and 1 Helpful Hints!!! Correct journal
More informationRESPONSE TO DECISION LETTER
RESPONSE TO DECISION LETTER Dear Editor-in-chief, We are grateful to the editors and reviewers for their time and constructive comments on our manuscript. We have implemented their comments and suggestions
More informationStreptococcus pneumoniae can cause a variety of clinical syndromes
Supplement Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Invasive Pneumococcal Disease Among Young Children Laura Conklin, MD,* Jennifer D. Loo, MPH,*
More informationWHO posi)on paper on pneumococcal vaccines. Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012
WHO posi)on paper on pneumococcal vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012 WHO posi)on paper on pneumococcal vaccines, April 2012 The current posi)on paper
More informationplural noun 1. a system of moral principles: the ethics of a culture. 2. the rules of conduct recognized in respect to a particular group, culture,
eth ics plural noun [eth-iks] 1. a system of moral principles: the ethics of a culture. 2. the rules of conduct recognized in respect to a particular group, culture, etc.: Scientific ethics; Medical ethics;
More informationInvasive pneumococcal disease
SURVEILLANCE REPORT Annual Epidemiological Report for 2016 Invasive pneumococcal disease Key facts In 2016, 21 986 confirmed cases of invasive pneumococcal disease (IPD) were reported in the EU/EEA. The
More informationEARSS in Ireland, Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance
EARSS in Ireland, 2007 Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance Antibiotic codes and abbreviations: CTX, Ciprofloxacin ERY, Erythromycin OXA, Oxacillin TCY, Tetracycline
More informationInvasive Pneumococcal Isolates from Danish Infants (0-90 Days) during the Years 1943 to 2013
Invasive Pneumococcal Isolates from Danish Infants (0-90 Days) during the Years 1943 to 2013 Hans-Christian Slotved*, Tine Dalby, Steen Hoffmann Neisseria and Streptococcus Reference Laboratory (NSRlab),
More informationTitle: Socioeconomic conditions and number of pain sites in women
Author's response to reviews Title: Socioeconomic conditions and number of pain sites in women Authors: Finn E Skjeldestad (fisk@fhi.no) Toril Rannestad (Toril.Rannestad@hist.no) Version: 2 Date: 17 January
More informationPneumococcal Conjugate Vaccine (PCV) Review of Impact Evidence (PRIME) Summary of Findings from Systematic Review October 2017 Olivia Cohen
Pneumococcal Conjugate Vaccine (PCV) Review of Impact Evidence (PRIME) Summary of Findings from Systematic Review October 2017 Olivia Cohen Contact: Kate O Brien, MD, MPH Executive Director, IVAC Johns
More information2. Could you insert a reference, proving your statement on p. 5, l. 66/67?
Author s response to reviews Title: Representative survey on idiopathic environmental intolerance attributed to electromagnetic fields in Taiwan and comparison with the international literature Authors:
More informationTitle:Video-confidence: a qualitative exploration of videoconferencing for psychiatric emergencies
Author's response to reviews Title:Video-confidence: a qualitative exploration of videoconferencing for psychiatric emergencies Authors: Marianne V Trondsen (marianne.trondsen@telemed.no) Stein Roald Bolle
More informationSession 6. Evaluating the Cost of Pharmaceuticals
Drug and Therapeutics Committee Training Course Session 6. Evaluating the Cost of Pharmaceuticals Trainer s Guide Drug and Therapeutics Committee Training Course Trainer s Guide This document was made
More informationTitle: Attitudes and beliefs of the French public about schizophrenia and major depression. Results from a vignette-based population survey
Reviewer's report Title: Attitudes and beliefs of the French public about schizophrenia and major depression. Results from a vignette-based population survey Version: 2 Date: 18 July 2013 Reviewer: Lori
More informationAssessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model
Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Aggarwal R, Ghoshal U C, Naik S R Record Status This is
More informationTennessee Immunization Program Updates
Tennessee Immunization Program Updates Kelly L. Moore, MD, MPH Medical Director, TN Immunization Program Tennessee Association of School Nurses Murfreesboro, Tennessee November 3, 2011 Objectives Recent
More informationSAGE evidence to recommendations framework i
SAGE evidence to recommendations framework i Question: What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old
More informationBody: Re Should the threshold for definition of impaired fasting glucose be lowered?
From: dme_editorial@wiley.com To: inouek@m.u-tokyo.ac.jp CC: dme_editorial@wiley.com Subject: Diabetic Medicine DME-2009-00292 Body: Re Should the threshold for definition of impaired fasting glucose be
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationTitle: The Limitations of Voluntary Medical Male Circumcision and the Importance of Sustained Condom Use: A Kenyan Newspaper Analysis
Author's response to reviews Title: The Limitations of Voluntary Medical Male Circumcision and the Importance of Sustained Condom Use: A Kenyan Newspaper Analysis Authors: Charlene N Muzyka (charlene.muzyka@gmail.com)
More informationWRITTEN ASSIGNMENT 1 (8%)
WRITTEN ASSIGNMENT 1 (8%) The purpose of this first written assignment is to give you practice at thinking scientifically about psychological issues. It s highly likely you have come across claims and
More information